PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-16.50%
Negative revenue growth while CVE stands at 3.53%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-25.93%
Negative gross profit growth while CVE is at 4.59%. Joel Greenblatt would examine cost competitiveness or demand decline.
-35.41%
Negative EBIT growth while CVE is at 21.54%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-35.41%
Negative operating income growth while CVE is at 21.54%. Joel Greenblatt would press for urgent turnaround measures.
-23.20%
Negative net income growth while CVE stands at 1151.18%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-22.73%
Negative EPS growth while CVE is at 840.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.73%
Negative diluted EPS growth while CVE is at 840.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.67%
Dividend reduction while CVE stands at 11.36%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
105.66%
OCF growth under 50% of CVE's 277.74%. Michael Burry might suspect questionable revenue recognition or rising costs.
32.76%
FCF growth under 50% of CVE's 5980.00%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
-83.97%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
12.11%
Positive 5Y CAGR while CVE is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
-48.06%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-91.64%
Negative 10Y OCF/share CAGR while CVE stands at 5.40%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-73.86%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-78.35%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-80.99%
Negative 10Y net income/share CAGR while CVE is at 1013.04%. Joel Greenblatt sees a major red flag in long-term profit erosion.
116.90%
Below 50% of CVE's 352.53%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-6.98%
Negative 3Y CAGR while CVE is 191.85%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-69.39%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-24.92%
Negative 5Y equity/share growth while CVE is at 34.12%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-24.12%
Negative 3Y equity/share growth while CVE is at 28.44%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-92.29%
Cut dividends over 10 years while CVE stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-92.79%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-78.68%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
9.14%
Our AR growth while CVE is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
No Data
No Data available this quarter, please select a different quarter.
2.14%
Asset growth well under 50% of CVE's 76.95%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
3.95%
Under 50% of CVE's 25.85%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
1.30%
Debt shrinking faster vs. CVE's 113.68%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
-14.81%
We cut SG&A while CVE invests at 34.88%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.